Frederic S Resnic1, Arjun Majithia1, Danica Marinac-Dabic1, Susan Robbins1, Henry Ssemaganda1, Kathleen Hewitt1, Angelo Ponirakis1, Nilsa Loyo-Berrios1, Issam Moussa1, Joseph Drozda1, Sharon-Lise Normand1, Michael E Matheny1. 1. From the Comparative Effectiveness Research Institute, Lahey Hospital and Medical Center, Burlington (F.S.R., A.M., S.R., H.S.), and Tufts School of Medicine (F.S.R., A.M.) and Harvard Medical School and the Harvard T.H. Chan School of Public Health (S.-L.N.), Boston - all in Massachusetts; the Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD (D.M.-D., N.L.-B.); the National Cardiovascular Data Registry, American College of Cardiology, Washington, DC (K.H., A.P.); First Coast Cardiovascular Institute and University of Central Florida College of Medicine, Jacksonville (I.M.); Mercy Health, St. Louis (J.D.); and the Veterans Affairs Tennessee Valley Healthcare System and Vanderbilt University, Center for Population Health Informatics, Departments of Biomedical Informatics, Biostatistics, and Medicine, Vanderbilt University Medical Center - both in Nashville (M.E.M.).
Abstract
BACKGROUND: The process of assuring the safety of medical devices is constrained by reliance on voluntary reporting of adverse events. We evaluated a strategy of prospective, active surveillance of a national clinical registry to monitor the safety of an implantable vascular-closure device that had a suspected association with increased adverse events after percutaneous coronary intervention (PCI). METHODS: We used an integrated clinical-data surveillance system to conduct a prospective, propensity-matched analysis of the safety of the Mynx vascular-closure device, as compared with alternative approved vascular-closure devices, with data from the CathPCI Registry of the National Cardiovascular Data Registry. The primary outcome was any vascular complication, which was a composite of access-site bleeding, access-site hematoma, retroperitoneal bleeding, or any vascular complication requiring intervention. Secondary safety end points were access-site bleeding requiring treatment and postprocedural blood transfusion. RESULTS: We analyzed data from 73,124 patients who had received Mynx devices after PCI procedures with femoral access from January 1, 2011, to September 30, 2013. The Mynx device was associated with a significantly greater risk of any vascular complication than were alternative vascular-closure devices (absolute risk, 1.2% vs. 0.8%; relative risk, 1.59; 95% confidence interval [CI], 1.42 to 1.78; P<0.001); there was also a significantly greater risk of access-site bleeding (absolute risk, 0.4% vs. 0.3%; relative risk, 1.34; 95% CI, 1.10 to 1.62; P=0.001) and transfusion (absolute risk, 1.8% vs. 1.5%; relative risk, 1.23; 95% CI, 1.13 to 1.34; P<0.001). The initial alerts occurred within the first 12 months of monitoring. Relative risks were greater in three prespecified high-risk subgroups: patients with diabetes, those 70 years of age or older, and women. All safety alerts were confirmed in an independent sample of 48,992 patients from April 1, 2014, to September 30, 2015. CONCLUSIONS: A strategy of prospective, active surveillance of a clinical registry rapidly identified potential safety signals among recipients of an implantable vascular-closure device, with initial alerts occurring within the first 12 months of monitoring. (Funded by the Food and Drug Administration and others.).
BACKGROUND: The process of assuring the safety of medical devices is constrained by reliance on voluntary reporting of adverse events. We evaluated a strategy of prospective, active surveillance of a national clinical registry to monitor the safety of an implantable vascular-closure device that had a suspected association with increased adverse events after percutaneous coronary intervention (PCI). METHODS: We used an integrated clinical-data surveillance system to conduct a prospective, propensity-matched analysis of the safety of the Mynx vascular-closure device, as compared with alternative approved vascular-closure devices, with data from the CathPCI Registry of the National Cardiovascular Data Registry. The primary outcome was any vascular complication, which was a composite of access-site bleeding, access-site hematoma, retroperitoneal bleeding, or any vascular complication requiring intervention. Secondary safety end points were access-site bleeding requiring treatment and postprocedural blood transfusion. RESULTS: We analyzed data from 73,124 patients who had received Mynx devices after PCI procedures with femoral access from January 1, 2011, to September 30, 2013. The Mynx device was associated with a significantly greater risk of any vascular complication than were alternative vascular-closure devices (absolute risk, 1.2% vs. 0.8%; relative risk, 1.59; 95% confidence interval [CI], 1.42 to 1.78; P<0.001); there was also a significantly greater risk of access-site bleeding (absolute risk, 0.4% vs. 0.3%; relative risk, 1.34; 95% CI, 1.10 to 1.62; P=0.001) and transfusion (absolute risk, 1.8% vs. 1.5%; relative risk, 1.23; 95% CI, 1.13 to 1.34; P<0.001). The initial alerts occurred within the first 12 months of monitoring. Relative risks were greater in three prespecified high-risk subgroups: patients with diabetes, those 70 years of age or older, and women. All safety alerts were confirmed in an independent sample of 48,992 patients from April 1, 2014, to September 30, 2015. CONCLUSIONS: A strategy of prospective, active surveillance of a clinical registry rapidly identified potential safety signals among recipients of an implantable vascular-closure device, with initial alerts occurring within the first 12 months of monitoring. (Funded by the Food and Drug Administration and others.).
Authors: Roxana Mehran; Martin B Leon; David A Feigal; David Jefferys; Michael Simons; Nicholas Chronos; Thomas J Fogarty; Richard E Kuntz; Donald S Baim; Aaron V Kaplan Journal: Circulation Date: 2004-06-29 Impact factor: 29.690
Authors: Frederic S Resnic; Thomas P Gross; Danica Marinac-Dabic; Nilsa Loyo-Berrios; Sharon Donnelly; Sharon-Lise T Normand; Michael E Matheny Journal: JAMA Date: 2010-11-10 Impact factor: 56.272
Authors: Robert G Hauser; Linda M Kallinen; Adrian K Almquist; Charles C Gornick; William T Katsiyiannis Journal: Heart Rhythm Date: 2007-04-10 Impact factor: 6.343
Authors: Christopher R Friese; Mandy Wong; Alex Fauer; Kari Mendelsohn-Victor; Martha Polovich; Marjorie C McCullagh Journal: Clin J Oncol Nurs Date: 2020-06-01 Impact factor: 1.027
Authors: Edward A Frankenberger; Frederic S Resnic; Henry Ssemaganda; Susan Robbins; Melissa R Dunbar; Paul Coplan; Shumin Zhang; Cortney Bruno; Mitchell Maltenfort; Jillian B Benedetti; Michael E Matheny; Zoher Ghogawala Journal: BMJ Surg Interv Health Technol Date: 2022-07-08
Authors: Joseph S Ross; Jonathan Bates; Craig S Parzynski; Joseph G Akar; Jeptha P Curtis; Nihar R Desai; James V Freeman; Ginger M Gamble; Richard Kuntz; Shu-Xia Li; Danica Marinac-Dabic; Frederick A Masoudi; Sharon-Lise T Normand; Isuru Ranasinghe; Richard E Shaw; Harlan M Krumholz Journal: Med Devices (Auckl) Date: 2017-08-16
Authors: Frederic S Resnic; Arjun Majithia; Sanket S Dhruva; Henry Ssemaganda; Susan Robbins; Danica Marinac-Dabic; Kathleen Hewitt; Lucila Ohno-Machado; Matthew R Reynolds; Michael E Matheny Journal: Circ Cardiovasc Qual Outcomes Date: 2020-04-14
Authors: Jonathan Bates; Craig S Parzynski; Sanket S Dhruva; Andreas Coppi; Richard Kuntz; Shu-Xia Li; Danica Marinac-Dabic; Frederick A Masoudi; Richard E Shaw; Frederick Warner; Harlan M Krumholz; Joseph S Ross Journal: Pharmacoepidemiol Drug Saf Date: 2018-06-12 Impact factor: 2.890
Authors: Prashant V Rajan; Jessica N Holtzman; Aaron S Kesselheim; Robert W Yeh; Daniel B Kramer Journal: J Am Heart Assoc Date: 2019-06-01 Impact factor: 5.501